Pharmaceutical giant Roche inaugurated Switzerland’s tallest building on Friday. The 205-metre-tall structure in Basel, known as Building 2, will house 3,500 workers.
The new high rise surpasses the firm’s nearby tower – Building 1 – which stands at 178 metres.
The new 50-floor high-rise office, with a total floor space of 83,000 metres, was designed by the renowned Swiss architectural firm Herzog & de Meuron; it cost CHF550 million ($561 million) to build.
The white, sleek staircase shaped towers can be seen from nearly everywhere in Basel in northwest Switzerland.
“Building 2 is another highly visible sign of Roche’s commitment to Basel – the city where Roche was founded over 125 years ago,” said Roche CEO Severin Schwan in a statementExternal link on Friday.
Tight planning regulation restrictions in many Swiss urban areas mean that there are few skyscrapers in Switzerland.
The construction of the twin towers in Basel allows Roche to bring together staff who were previously working in different locations across the city. Two thousand employees work in Building 1.
The pharma giant is continuing its investment in Basel with plans for a new CHF1.2 billion research & development centre, which is due to open in autumn 2024.
Roche is one of the biggest private employers in Switzerland with 15,000 staff based on four sites (two in Basel, and others in Zurich and Rotkreuz); it employs 100,000 people worldwide.
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
Swiss voters to decide on three issues on November 30
This content was published on
Compulsory service for all, a tax on million-dollar inheritances, more indirect subsidies for media publishers: the electorate can vote on these three national issues on November 30.
Dollar falls to lowest level against franc in 14 years
This content was published on
The weakness of the dollar in recent weeks continues. The greenback hit new lows for the year against both the franc and the euro on Tuesday.
This content was published on
Swiss President Karin Keller-Sutter has met French President Emmanuel Macron to discuss the EU treaties and geopolitical challenges. US tariffs were also part of the bilateral talks.
This content was published on
Swiss moors and floodplains are in a poor state. Researchers say further efforts are needed to preserve these biotopes in the long term.
Drones banned during the three Euro games in St Gallen
This content was published on
The St. Gallen government has issued a temporary ban on flying drones around the football stadium in St. Gallen. The measure will apply on three match days of Euro 2025, which starts on Wednesday.
EU nationals come to Switzerland primarily to work
This content was published on
Given the demographic slowdown, the Swiss labour market must remain open, argues the State Secretariat for Economic Affairs (SECO) in its annual report on the free movement of people.
UN expert accuses Glencore of complicity with Israel
This content was published on
The UN Special Rapporteur on the Palestinian Territories has accused Zug-based Glencore of profiting from an Israeli economy that has become "an economy of genocide".
Swiss parliamentary commission to investigate F-35 purchase
This content was published on
The Swiss government and the other responsible authorities must once again answer critical questions about the procurement of the F-35 fighter jets.
Objections and appeals most common obstacles to residential construction projects
This content was published on
Objections and appeals are most frequently responsible for delays in new residential construction projects in Switzerland.
Swiss electricity prices predicted to fall in 2026
This content was published on
Electricity prices in 2026 are likely to be lower than this year, according to a survey. The main reason is the fall in prices on the electricity market.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
What’s behind the Novartis job cuts?
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure - it’s a turning point for Novartis.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.